Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia
Authors
Keywords
-
Journal
Asia Pacific Journal of Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-09-20
DOI
10.1111/ajco.14001
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.
- (2023) Aristotelis Bamias et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study.
- (2023) Matt D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.
- (2022) Yohann Loriot et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.
- (2022) Simon J. Crabb et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
- (2022) Matt D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
- (2022) Javier Cortés et al. NEW ENGLAND JOURNAL OF MEDICINE
- RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials.
- (2022) Xinan Sheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2 expression in urothelial carcinoma, a systematic literature review
- (2022) Emilie Scherrer et al. Frontiers in Oncology
- EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.
- (2021) Arjun Vasant Balar et al. JOURNAL OF CLINICAL ONCOLOGY
- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
- (2021) Ahmet Sezer et al. LANCET
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
- (2021) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
- (2021) Scott T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Atezolizumab in Under Studied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice
- (2021) Axel S. Merseburger et al. JOURNAL OF UROLOGY
- Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.
- (2021) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- (2021) Thomas Powles et al. LANCET ONCOLOGY
- Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation
- (2021) Kyu Sang Lee et al. Journal of Pathology and Translational Medicine
- A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinoma
- (2021) Shoma Yamamoto et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling
- (2021) Jin-Fen Xiao et al. Cancers
- Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- (2021) T. Powles et al. ANNALS OF ONCOLOGY
- Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
- (2020) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
- (2020) Thomas W. Flaig et al. Journal of the National Comprehensive Cancer Network
- ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.
- (2020) Arlene O. Siefker-Radtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
- (2020) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- (2020) Matthew D Galsky et al. LANCET
- Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
- (2020) Jacqueline Vuky et al. JOURNAL OF CLINICAL ONCOLOGY
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive value of fibroblast growth factor receptor (FGFR) mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients (pts) with advanced urothelial cancer (UC).
- (2019) Ademi E. Santiago-Walker et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
- (2019) Y Fradet et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors
- (2019) Ali Raza Khaki et al. CANCER
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Impact of the Number of Cycles of Platinum Based First Line Chemotherapy of Advanced Urothelial Carcinoma
- (2018) Guru P. Sonpavde et al. JOURNAL OF UROLOGY
- Systemic treatments for metastatic urothelial carcinoma
- (2018) Aly-Khan A. Lalani et al. EXPERT OPINION ON PHARMACOTHERAPY
- Gemcitabine Plus Cisplatin Split Versus Gemcitabine Plus Carboplatin for Advanced Urothelial Cancer With Cisplatin-unfit Renal Function
- (2018) KOUJI IZUMI et al. IN VIVO
- Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
- (2017) Sebastien Antoni et al. EUROPEAN UROLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
- (2017) Jesus García-Donas et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Epidemiology of Locally Advanced or Metastatic Urothelial Cancer In The US, Europe And Japan
- (2017) M Bharmal et al. VALUE IN HEALTH
- The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
- (2016) Jennifer L. Hsu et al. CANCER AND METASTASIS REVIEWS
- Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
- (2016) P. M. Challita-Eid et al. CANCER RESEARCH
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome
- (2016) Holly L Harper et al. MODERN PATHOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations
- (2015) Jeffrey S. Ross et al. CANCER
- Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma
- (2015) Yi Rang Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin as First-Line Therapy for Advanced Urothelial Carcinoma
- (2013) Benjamin L. Maughan et al. Clinical Genitourinary Cancer
- Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
- (2012) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma
- (2011) M. D. Galsky et al. ANNALS OF ONCOLOGY
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
- (2011) Maria De Santis et al. JOURNAL OF CLINICAL ONCOLOGY
- A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy
- (2011) Matthew D Galsky et al. LANCET ONCOLOGY
- Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers
- (2010) R. S. van der Post et al. JOURNAL OF MEDICAL GENETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started